Publication Name	World Journal of Cardiology
Manuscript ID	34563
Country	United States

Received	2017-05-06 15:48
Peer-Review Started	2017-05-10 10:32
To Make the First Decision	2017-05-23 00:53
Return for Revision	2017-06-12 06:23
Revised	2017-07-31 23:17
Second Decision	2017-08-11 07:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-08-16 01:12
Articles in Press	2017-08-16 01:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-13 06:29
Publish the Manuscript Online	2017-09-25 02:01

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Systematic Reviews
Article Title	Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review
Manuscript Source	Invited Manuscript
All Author List	Melorin Mehrzad, Rasikh Tuktamyshov and Raman Mehrzad
ORCID	Author(s) ORCID Number Melorin Mehrzad http://orcid.org/0000-0002-7578-2720 Rasikh Tuktamyshov http://orcid.org/0000-0002-7578-2721 Raman Mehrzad http://orcid.org/0000-0002-7578-2719
Funding Agency and Grant Number
Corresponding Author	Raman Mehrzad, MD, Department of Internal Medicine, Yale New Haven Hospital, Yale School of Medicine, 20 York St., New Haven, CT 06510, United States. raman.mehrzad@ynhh.org
Key Words	Efficiency; Cost effectiveness; Bivalirudin; Safety
Core Tip	Bivalirudin is a direct thrombin inhibitor used in clinical practice since 1990’s. It was initially introduced as an alternative medication to heparin during percutaneous coronary intervention. Early studies showed advantages of bivalirudin over heparin. We did a systematic review of the literature since 1990 and summarized all relevant trials. The majority showed better outcomes with bivalirudin. However, some trials are difficult to compare directly as protocols and patient populations differ. Bivalirudin and heparin are both acceptable options according to current ACA/AHA guidelines. Authors conclude however, that that due to bivalirudin safer bleeding profile, it should be the preferred medication for anticoagulation.
Publish Date	2017-09-25 02:01
Citation	Mehrzad M, Tuktamyshov R, Mehrzad R. Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review. World J Cardiol 2017; 9(9): 761-772
URL	http://www.wjgnet.com/1949-8462/full/v9/i9/761.htm
DOI	http://dx.doi.org/10.4330/wjc.v9.i9.761

Full Article (PDF)	WJC-9-761.pdf
Full Article (Word)	WJC-9-761.doc
Manuscript File	34563-Review.docx
Answering Reviewers	34563-Answering reviewers.pdf
Audio Core Tip	34563-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	34563-Conflict-of-interest statement.pdf
Copyright License Agreement	34563-Copyright assignment.pdf
Supplementary Material	34563-Supplementary-Material-revision.docx
Peer-review Report	34563-Peer-review(s).pdf
Scientific Misconduct Check	34563-Scientific misconduct check.pdf
Scientific Editor Work List	34563-Scientific editor work list.pdf